3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
175
Leukemia
147
Myelodysplastic Syndromes
138
Precursor Cell Lymphoblastic Leukemia-Lymphoma
112
Lymphoma
99
Lymphoma, Non-Hodgkin
86
Multiple Myeloma
81
Hodgkin Disease
74
Leukemia, Lymphocytic, Chronic, B-Cell
69
Congenital Abnormalities
62
Leukemia, Myeloid, Chronic-Phase
60
Myeloproliferative Disorders
57
Lymphoma, Large B-Cell, Diffuse
56
Neoplasms, Plasma Cell
53
Leukemia, Myelomonocytic, Chronic
53
Leukemia, Myeloid, Accelerated Phase
52
Lymphoma, Follicular
51
Lymphoma, Mantle-Cell
47
Burkitt Lymphoma
46
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
45
Lymphoma, B-Cell, Marginal Zone
44
Lymphoma, Large-Cell, Immunoblastic
43
Blast Crisis
43
Anemia, Refractory, with Excess of Blasts
43
Primary Myelofibrosis
40
Recurrence
36
Hematologic Neoplasms
35
Graft vs Host Disease
35
Myelodysplastic-Myeloproliferative Diseases
34
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
32
Interventions
Cyclophosphamide
3
fludarabine phosphate
2
fludarabine
2
AP 1903 reagent
2
thymoglobulin
1
ruxolitinib
1
Whole-Body Irradiation
1
Tacrolimus
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Panobinostat
1
Mycophenolic Acid
1
Mesna
1
Dexamethasone
1
Busulfan
1
Bortezomib
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thalassemia
×
Busulfan
×
Clear all
NCT00578292
2020-05-01
THALLO
Baylor College of Medicine
Phase NA
Terminated
10 enrolled
15 charts